Methods for Predicting and Monitoring Cancer Patients' Response to Teatment by Measuring Myeloid Derived Suppressor Cells (MDSCs)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Aug 19, 2015
filing date -
Aug 19, 2014
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Provided herein are methods and kits for predicting and monitoring a cancer patient's response to treatment with a therapeutic agent by measuring the amount of myeloid derived suppressor cells (MDSC) having the profile CDl11b+CD33+HLA-DR− and/or CDl11b+CD33+HLA-DRlow, and optionally by further measuring various suppressive features of the patient's immune system. Also provided herein are methods of treating a cancer patient comprising as an initial step determining whether the cancer patient would be responsive to treatment with the therapeutic agent as described above and wherein the patient is found to be responsive, administering the therapeutic agent.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully